Infections and anti-tumor necrosis factor alpha therapy.
about
Advances in rheumatology: new targeted therapeuticsProphylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patientsProphylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patientsAnti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safetyEffect of adalimumab on neutrophil function in patients with rheumatoid arthritisDermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study.Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in AsiaRisk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.Is There a Potential Role for Anti-tumor Necrosis Factor Therapy in Patients with Human Immunodeficiency Virus?Allicin: chemistry and biological properties.Opposite role of tumor necrosis factor receptors in dextran sulfate sodium-induced colitis in mice.Chronic necrotizing pulmonary aspergillosis in a patient treated with a tumor necrosis factor-alpha inhibitor.Prevention of progressive joint destruction in collagen-induced arthritis in rats by a novel matrix metalloproteinase inhibitor, FR255031.Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection.Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonistsLong term safety of etanercept in elderly subjects with rheumatic diseases.The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview.Tumor necrosis factor-alpha deficiency impairs host defense against Streptococcus pneumoniaeAnakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis.Considerations with the use of biological therapy in the treatment of rheumatoid arthritis.Serious infections associated with anticytokine therapies in the rheumatic diseases.All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists.Psoriasis: emerging therapeutic strategies.Infliximab for the treatment of early rheumatoid arthritis.Infliximab for the treatment of ankylosing spondylitis.Update on tuberculosis and other opportunistic infections associated with drugs blocking tumour necrosis factor {alpha}American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States.Anti-TNF-alpha agents in the treatment of psoriatic arthritis.Safety and efficacy of anti-tumor necrosis factors α in patients with psoriasis and chronic hepatitis CPathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatmentClinical characteristics and treatment responses of patients who developed tuberculosis following use of a tumor necrosis factor-α inhibitor.The immune response in inflammatory bowel disease.Etanercept: long-term clinical experience in rheumatoid arthritis and other arthritis.The use of TNF-alpha blocking agents in rheumatoid arthritis: an update.Safety of cyclosporin A in HCV-infected patients: experience with cyclosporin A in patients affected by rheumatological disorders and concomitant HCV infection.Current understanding of Pneumocystis immunology.Disruption of Early Tumor Necrosis Factor Alpha Signaling Prevents Classical Activation of Dendritic Cells in Lung-Associated Lymph Nodes and Development of Protective Immunity against Cryptococcal Infection.TNF-alpha is a positive regulatory factor for human Vgamma2 Vdelta2 T cells.Adenoviral pneumonia during etanercept treatment in a patient with rheumatoid arthritis.Treatment of ankylosing spondylitis: focus on etanercept.
P2860
Q21093257-A6F03AAB-B685-42EA-BA07-C8E1AFBEDBC6Q24193204-462302D0-847A-42A0-8AB0-1094AD321ED6Q24243871-E60837D0-A7C5-4A72-81EA-914F13E1C181Q24673716-69DE5AEB-C591-41DA-A347-F787F906A6E3Q24803670-B84835BE-DC5D-471D-8651-38A9D48D0FA1Q24816844-7B24B250-5AFA-4620-B4E5-EE31BA16824CQ33667789-B9C5E4FC-794A-43AB-BE2B-5B540825B9A0Q34065405-38A054F5-5EDF-465C-9807-DA8FB3F9EC36Q34074149-DB18B55B-3308-48C5-A77F-CD25A1CE6AFBQ34434941-064E4CC4-680A-48DB-ABDA-FFB60C1476F0Q34534877-C2E6A267-96C0-48CC-B9D8-66DD26D3E2C4Q34622449-B3C10334-37B8-4DC5-BADB-3AAE2687A384Q35048514-40A9AD29-CD91-43A1-A569-13C8228FF9E8Q35579382-D5DBA88E-F4D6-4321-8D7C-C1F27F519B90Q35605635-D7D243E1-05A8-4908-92D8-AAFD89BE7E51Q35636875-893A7644-D761-4786-8DE4-80E162CDA48BQ35688168-E036429A-5C2C-4F39-9B85-8A60C493DA57Q35812602-286F98C0-9EDB-4A30-BDBC-324057210A6FQ35842626-DCD29230-B02A-4954-BB01-64432372C699Q35873708-17BF42D7-8488-4326-B634-0EAED57D90E2Q35937819-A5388682-B71E-4A9C-90C2-00673C2DD084Q35954490-DCC47F0A-BC55-4787-B6E2-FC9EAEF1670DQ36028220-C4D32C5E-8BD2-4BDE-B3E3-1037B580AE6AQ36099482-FCAA8C29-5962-42B5-AE20-091AC7ED7518Q36210882-D3969ED8-28E6-405D-93B4-EB272DF31629Q36292628-915FD2B0-2383-4404-BAD0-A0C5F47204D4Q36297088-DB632DF4-9EFA-4514-9C3B-AD5FE59EBC6BQ36377196-59FF9F97-1539-4D36-A7BC-872AD4B0C172Q36522235-C06EFB3C-69A0-45B3-8A60-51EF60BC901EQ36525240-04AE427D-B142-4063-B20F-1E03802A750AQ36705704-A7E325EF-A51B-4420-AB20-31606E289886Q36846736-6A9680CE-E23C-4597-894C-3110CCFCA633Q36847326-B21122E4-295E-4356-9070-E9C5F71B1B1AQ36916918-B01D263F-9EF0-4ECC-9ABE-4E94E7D5B149Q36958375-9F74D2A4-0F46-4B73-AF56-283F5CE53C04Q36984703-52207D2C-58D5-477B-8A83-7D43565E29B5Q37120228-3F4CCBB8-A741-4B42-8EDA-63A39724BE1EQ37120229-E89CA315-5ABA-4EDD-B43F-94096636BEC8Q37205173-35D2BE34-C313-4CFE-A50F-FB2F4ACB42BDQ37290601-CEDCEBA6-2920-4267-ACE5-5197AED2E49B
P2860
Infections and anti-tumor necrosis factor alpha therapy.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Infections and anti-tumor necrosis factor alpha therapy.
@ast
Infections and anti-tumor necrosis factor alpha therapy.
@en
type
label
Infections and anti-tumor necrosis factor alpha therapy.
@ast
Infections and anti-tumor necrosis factor alpha therapy.
@en
prefLabel
Infections and anti-tumor necrosis factor alpha therapy.
@ast
Infections and anti-tumor necrosis factor alpha therapy.
@en
P2093
P356
P1476
Infections and anti-tumor necrosis factor alpha therapy.
@en
P2093
Michael E Weinblatt
Robert H Rubin
Todd Ellerin
P304
P356
10.1002/ART.11301
P577
2003-11-01T00:00:00Z